Comparative Pharmacology
Head-to-head clinical analysis: LAZANDA versus STADOL PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAZANDA versus STADOL PRESERVATIVE FREE.
LAZANDA vs STADOL PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein-coupled receptors to inhibit adenylate cyclase, reduce cAMP production, and modulate ion channels, leading to decreased neurotransmitter release (e.g., substance P, glutamate) and hyperpolarization of neurons, resulting in analgesia and sedation.
Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.
100 mcg (one spray) intranasally as needed for breakthrough pain; may repeat once after 15-30 minutes if needed; do not exceed 2 doses per episode and 4 doses per day.
0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.
None Documented
None Documented
Terminal elimination half-life: 6–10 hours (mean approximately 7 hours) following nasal administration; prolonged in hepatic impairment.
Terminal elimination half-life is 2.5–3.3 hours in adults; prolonged to 4–6 hours in elderly or hepatic impairment.
Renal excretion of metabolites (mostly fentanyl metabolites, primarily norfentanyl): approximately 75%; fecal excretion: approximately 9%; less than 10% excreted as unchanged fentanyl in urine.
Primarily hepatic metabolism (glucuronidation) to inactive metabolites; renal excretion accounts for <5% unchanged drug. Approximately 70% of dose excreted in urine as metabolites, 20% in feces.
Category C
Category C
Opioid Analgesic
Opioid Analgesic